Evidence-Based Complementary and Alternative Medicine

Evidence-Based Complementary and Alternative Medicine / 2018 / Article

Research Article | Open Access

Volume 2018 |Article ID 8590381 | https://doi.org/10.1155/2018/8590381

Patrick Amoateng, Emmanuel Quansah, Thomas K. Karikari, Alex Asase, Dorcas Osei-Safo, Kennedy Kwami Edem Kukuia, Isaac Kingsley Amponsah, Alexander K. Nyarko, "Medicinal Plants Used in the Treatment of Mental and Neurological Disorders in Ghana", Evidence-Based Complementary and Alternative Medicine, vol. 2018, Article ID 8590381, 14 pages, 2018. https://doi.org/10.1155/2018/8590381

Medicinal Plants Used in the Treatment of Mental and Neurological Disorders in Ghana

Academic Editor: Youn C. Kim
Received11 Sep 2018
Accepted29 Nov 2018
Published20 Dec 2018

Abstract

Ethnopharmacological Relevance. Mental and neurological disorders are a serious public health challenge globally, particularly in developing countries where cultural factors and limited access to standard healthcare have led to a reliance on traditional medicines. However, ethnopharmacological characterization of traditional medicines used to treat these diseases is lacking. In this study, an ethnobotanical description of plant species used in treating mental and neurological disorders in Ghana and an update of their experimentally validated pharmacological relevance are provided. Materials and Methods. Two hundred herbalists agreed to participate but sixty-six specialized in treating mental and neurological disorders were interviewed on their traditional medical practice. Literature review was conducted to verify the experimentally validated pharmacological importance of the reported plants. Results. Thirty-two plant species belonging to twenty-eight families were identified. Most plant species had either analgesic (50%), anxiolytic (18.8%), or anticonvulsant (15.6%) properties. Others had reported sedative, anti-Alzheimer’s disease, motor coordination, antipsychotic, antidepressant, cognitive enhancement, and neuroprotective properties. While Ageratum conyzoides L. (Asteraceae) and Ocimum gratissimum L. (Lamiaceae) were the most commonly mentioned species with analgesic properties, Lantana camara L. (Verbenaceae) was the most-reported anxiolytic product, with Cymbopogon citratus DC. (Gramineae), Mangifera indica L., Tetrapleura tetraptera Schum Taub. (Fabaceae), and Persea Americana Mill (Lauraceae) being the most studied anticonvulsants. Conclusions. This study provides the first report specifically on medicinal plants used in treating mental and neurological disorders in Ghana. Most of the identified plants have been scientifically confirmed to possess neuro- and psychopharmacological properties and may serve as templates for drug development.

1. Introduction

The World Health Organization (WHO) estimates that more than one billion people suffer from central and peripheral nervous system (CNS/PNS) disorders globally [1, 2]. These diseases include Parkinson’s disease, epilepsy, schizophrenia, bipolar disorder, Alzheimer’s disease and other dementias, neuroinfections, brain tumors, traumatic disorders, and cerebrovascular diseases such as stroke and migraine. More than 6 million people reportedly die each year due to stroke, with over 80% of these deaths occurring in low- and middle-income countries [2]. Moreover, although little research attention has been paid to diseases such as schizophrenia, bipolar disorder, and other psychotic disorders in Africa, some studies have shown that schizophrenia is a major psychiatric diagnosis leading to in-patient admissions on these continents [36]. In addition, the CNS/PNS disease burden in Africa is exacerbated by the numerous but understudied neurological impairments associated with common tropical diseases such as the neglected tropical diseases [7].

Ghana is host to a wide array of medicinal flora and takes pride in the longstanding cultural use of traditional and alternative medicines (TAMs), as exhibited by the several published works on the ethnobotanical use of TAMs in the country [811]. Nonetheless, there are concerns about the safety and efficacy claims of some TAMs [12]. In order to address these concerns while enhancing the therapeutic potentials of TAMs and ensuring minimum adverse effects, the Ghanaian Government, academics, and TAM practitioners have institutionalized measures to regulate herbal medicine practice and also integrate TAMs into the mainstream healthcare system. For example, the Ghana Federation of Traditional Medical Practitioners Association (GHAFTRAM) was established in 1999 to help modernize, restructure, and regulate the traditional medical industry in the country [13]. GHAFTRAM has members from all parts of Ghana, working together towards advancing the development of TAMs. In addition, an undergraduate program in herbal medicine which complements university training with hands-on internships at a herbal medicine research centre as well as herbal and allopathic practitioners has been established [14]. On passing their professional qualifying examination, graduates are certified and regulated by Ghana’s Traditional Medical Practice Council, and some are employed by the Government to practice as medical herbalists in herbal clinics established within public hospitals to work in partnership with medical and allied health staff to provide curative and preventive medical care [12, 14].

The foregoing measures emphasize that TAMs continue to play a significant role in the treatment of various disorders including those of CNS/PNS origin [1517]. However, there have been no studies focusing primarily on the documentation of traditional methods of treating mental and neurological disorders in Ghana, and how these may inform healthcare practice, policy, and drug development. Consequently, comprehensive information on plant species, plant parts used, cultural practices, and methods of preparation and use of these TAMs are lacking. Moreover, the therapeutic potential, CNS properties, and the safety profile of most of these products are largely unknown. The present study sought to address this knowledge gap by using a guided survey to document TAMs used in the treatment of mental and neurological disorders in Ghana based on traditional knowledge. Moreover, we aimed to ascertain the scientifically confirmed pharmacological relevance of these medicinal products that may justify their clinical use and further research to isolate compounds of interest to drug discovery and development. Specifically, the study was aimed at (a) identifying commonly used TAMs for CNS/PNS disorders and their modes of preparation and (b) documenting the therapeutic potentials of these products.

2. Materials and Methods

2.1. Selection of Participants, Obtaining prior Informed Consent, Ethical Approval, and Data Collection

An ethnobotanical approach was used to explore the knowledge and treatment practices of mental and nervous system disorders by traditional medical practitioners (TMPs) from various districts and subdistricts of the Greater Accra and Brong-Ahafo regions of Ghana. Study participants were TMPs who were all members of GHAFTRAM attending a meeting in Accra. The study objectives, method, and planned use of information were explained to the TMPs before the interviews. Among the 200 TMPs present at the GHAFTRAM meeting, 66 were included in this study. The excluded delegates were not specialized in the treatment of mental and neurological diseases, as they found such patients quite difficult to manage.

A guided questionnaire interview approach was used: during the interviews conducted in both English and Twi, a local Ghanaian dialect, information on the types and parts of plant materials used, the methods of preparation, the local names of plants, and the mode of administration of herbal products were obtained. To be included in the interview, one had to be a (a) TMP practicing in Ghana, potentially treating mental and neurological diseases directly or having some level of knowledge on products used in treating such patients or (b) registered member of GHAFTRAM willing to participate in the survey. Approval for this study was granted by the Scientific and Technical Committee of the Noguchi Memorial Institute for Medical Research, Accra, Ghana, reference number STC-4 (2) 2013-14. Prior to the study, permission was granted from the leadership of GHAFTRAM and all participants duly signed informed consents.

2.2. Data Management and Analysis

A list of the plants obtained from the survey was subjected to thorough review using Internet search engines (such as google scholar) and journal databases such as Medline, Embase, Scopus, and Pubmed to confirm their therapeutic potential. A search of Ghanaian and West African herbal pharmacopoeias was done using the following search terms: “neurological disorders”, “psychiatric disorders”, “schizophrenia”, “Parkinson’s disease”, “Alzheimer’s disease”, and “mental disorders” in combination with either “Ghana”, “West Africa”, or “Africa”.

Data obtained from the ethnobotanical study were analyzed using the Statistical Package for Social Sciences version 22.0 for Windows.

3. Results

3.1. Sociodemographic Characteristics of Respondents

In total, 66 TMPs were interviewed: 65 and 1 from the Greater Accra and Brong-Ahafo regions, respectively. About 56.1% were males and 43.9% were females. About 40.9% of the TMPs were either 50-59-year-old or 60 years and above (27.3%). In addition, while 65.2% were married, 22.7% were single, 10.6% were widowed, and 1.5% were divorced. Most TMPs had either primary school (53.1%) or secondary school (28.1%) education (Table 1); only 10.9% had some form of postsecondary education.


VariableFrequencyPercentage ()

Sex
Male3756.1
Female2943.9

Age (years)
20-2911.5
30-39812.1
40-491218.2
50-592740.9
60 and above1827.3

Marital status
Single1522.7
Married4365.2
Divorced11.5
Widowed710.6

Highest educational level
No Education57.8
Primary3453.1
Secondary1828.1
Tertiary710.9

3.2. Source of the Knowledge of Herbal Medicine Practice and Duration of Practice

The TMPs’ knowledge of traditional healing, including knowledge to treat mental and neurological disorders, was mainly acquired from relatives (Figure 1). About 36.5% had practiced for 16-20 years, while 27% had practiced for 1-5 years (Table 2).


VariableFrequencyPercentage ()

Source of the knowledge of herbal medical practice
Inheritance (knowledge passed on from others)3863.3
Divine/spiritual1423.3
Formal training813.3

Years of herbal medical practice
1-51727.0
6-101015.9
11-151320.6
16-202336.5

3.3. Treatment of Mental and Neurological Diseases

Most of the TMPs (60.6%) had specific herbs for treating a variety of mental and neurological disorders. However, only 36.4% had actually treated such patients. Out of these, 19.7% had treated a maximum of 5 patients, with only 1.5% having treated more than 20 patients. Overall, 31.8% of the treated patients had completely recovered (Table 3).


VariableFrequency (n)Percentage ()

Knowledge of herbs for treating mental and neurological disorders
No2639.4
Yes4060.6

Total number of patients treated throughout herbal medical practice
04263.6
1-51319.7
6-1057.6
11-1534.5
16-2023.0
Above 2011.5

Treatment options used
Not applicable4263.6
Divine/spiritual only11.5
Herbs only1624.3
Herbs and divine/spiritual710.6

Recovery status of patients treated
Not applicable/no recovery4263.6
Partial recovery34.5
Total recovery2131.8

3.4. Species, Medicinal Uses, and Experimentally Validated Pharmacological Relevance of Plants

In all, 32 plant species were provided by the TMPs and these came from 28 different plant families (Table 4). The families Apocynaceae, Asteraceae, and Meliaceae were the most mentioned plant families, with Apocynaceae having the highest frequency of mentions and Asteraceae having the highest number of plant species (Figure 2). Rauwolfia vomitoria Afz. was the plant with the highest frequency of mention (mentioned 7 times; Figure 3). About 66% of the plants (21 species) used have been previously reported to have neuropharmacological activities. Half of the identified TAMs had analgesic (50%) properties, with the others having anxiolytic (18.8%), sedative (6.3%), anticonvulsant (15.6%), and antidepressant (9.4%) properties. R. vomitoria Afz., belonging to the family Apocynaceae, however, has been previously reported to have antipsychotic properties [16, 18] (Table 5).


SpeciesFamily Growth forms Local names in different languagesVoucher specimen Frequency of mentionPlant part usedMethod of preparation

Ageratum conyzoidesAsteraceaeHerbEwe: mima, Nyigbe; Fante: Ahaban Kankan, Efumomoe; Twi: Gu-ekuro, Adwoa-kura, Guakuo, Gu-ekura; Nzema: Ebuakulo; Ga-Dangme: NtumumuPA01/UGSOP/GH173LeavesThe fresh leaves are macerated and the liquid obtained is instilled into the nostrils; the fresh leaves can also be boiled, sieved and drank as required.
Allium sativumLiliaceaeHerbTwi: Gyene Kankan; Ga Adangme: Aya; Hausa: TafarmuwaPA02/UGSOP/GH172Whole plant-
Alstonia booneiApocynaceaeTreeTwi: Nyame-dua, Nyamedua, Onyamedua, Osen Nuru; Ewe: Siaketreke Fante: Nyena,Sinuro,Nyamedua; Nzema: BakuninPA03/UGSOP/GH172BarkThe leaves are boiled and drank as required
Azadiratcha indicaMeliaceaeTreeFante: Nim, Aboode,Abodua; Ewe: Liliti; Ga-Dangme: Kintso, Asante: Gyedua; Twi: Nimsi, Dua gyanePA04/UGSOP/GH171Leaves; RootsThe boiled leaves/roots are drank as required
Bertholletia excelsLecythidaceaeBrazil nutPA05/UGSOP/GH171Nut; LeavesThe leaves/nuts are boiled and sieved extract is drank as required
Bidens pilosa.AsteraceaeHerbTwi: Dwirentwi,Gyinantwi; Ewe: Dzanikpikpi;PA06/UGSOP/GH171LeavesThe fresh leaves are macerated and the liquid obtained is instilled into the nose
Blighia unijucataSapindaceaeTreeAsante: Akye, Akan, Akyibiri, Twi: Akyebiri, Fante: EteduaPA07/UGSOP/GH173Bark; RootsThe dried barks/roots are boiled and drank as required, the extract can also be smeared on the body
Cassia occidentalis.CaesalpiniaceaeNkwadowa bɔdeɛPA08/UGSOP/GH173LeavesThe leaves are boiled and drank as required
Cinchona pubescensRubiaceaeShrubPA09/UGSOP/GH171
Citrus aurantifoliaRutaceaeTwi: Ankaadwea, Akenkaa Ankaatwaree; Fante: Ankama, Ewe: Mumoe; Asante: Ankaatwaree; Dagbani: Nyamsa, Lim buri; Ga-Adangme: Abonua; Hausa: Olomankilisi; Nzema: Domunli; Mole: Leemu; Ga: KpetePA10/UGSOP/GH171Peel; JuiceThe peels are squeezed directly on the forehead and into the nose
Cocos nuciferaPalmaeTreeTwi: kube; Ewe: AgonePA11/UGSOP/GH171JuiceDrinking the fresh coconut juice at will
Corchorus olitoriusTiliaceaeHerbaceousEwe: Ademe,Singui; Fante: Oturo; Twi: OtoroPA12/UGSOP/GH171Jute mallow, LeavesHot infusion is made from the leaves and drank as required
Cymbopogon citratusGraminaeHerbEwe: Tigbe; Fante: Ti ahaban, Ga-Dangme:Ti-baPA13/UGSOP/GH171Leaves; OilA decoction is made from the either the fresh/dried leaves and the oily content applied as a massage
Eucalyptus globulus MyrtaceaeEucalyptusPA14/UGSOP/GH171OilCold infusion is made and the oily content obtained is rubbed on the body
Khaya senegalensisMeliaceaeTreeHausa: Madwachi, Madachi; Ewe: Logo; Fante: Okum; GaAdangme: Kuga; Twi: Kuntunkuri; Mole: Kuka; Brong: Korobaa; Nzema: AnanePA15/UGSOP/GH174BarkThe leaves are boiled and drank as required
Lantana camara VerbenaceaeShrubAkan,Ananse dokonoPA16/UGSOP/GH173Leaves; StemThe leaves/stem are boiled and the liquid obtained, drank as required
Mangifera indicaAnacardiaceaeTreeEwe/Asante/Twi/ Fante Mango, Amango,Ga: MangoPA17/UGSOP/GH171BarkA decoction is made from the dried bark and drank as required
Momordica charantiaCucurbitaceaeHerbaceousTwi: Nyannya, Nyina, Nyinya; Ewe: Kakle; Dangme: Nyanyla, Nyanyra; Ga: Nyanyra; Nzema: NyanyaPA18/UGSOP/GH171
Musa paradisiacaMusaceaeHerbaceousTwi: Brode; Nzema: Banna Ga: AmadaaPA19/UGSOP/GH171LeavesThe leaves are boiled and drank as required
Nephrolepis cordifolia NephrolepidaceaeTwi: MmɛnPA20/UGSOP/GH171LeavesThe leaves are macerated and the liquid instilled nasally or inhaled. The leaves can be boiled and the extracted liquid used as a bathing liquid.
Occimum gratissimumLamiaceaeShrubEwe: Babusui, Dzeveti; Ga: Sulu; Twi: Onunum, Nunum; Asante: Nunum; Ga-Dangme: Sulu; Hausa: Dardoyatagidi; Nzema: Amaloko; Wassa: Aprim; Fante: OnunumPA21/UGSOP/GH173LeavesThe leaves are boiled and drank as required
Passiflora edulisPassifloraceaePassion fruit treePA22/UGSOP/GH172Leaves; Flowers; Fruit; LeavesBoiling; grinding
Persea americanaLauraceaeTreeDangme: Paya; Twi: Pee; Akan: Paya, Pae;PA23/UGSOP/GH171Fresh and dried leavesA decoction is made from the either the fresh/dried leaves and drank as required
Fante: Pae;
Phyllantus nuririEuphobiaceaeHerbaceousTwi: Awommaguwakyi; Ewe: Lane; Krobo: Ofobiokpai, Ofobi; Ga: Omatsoatsi;PA24/UGSOP/GH171
Rauwolfia vomitoria.ApocynaceaeShrubTwi: Kakapenpen; Ewe: Dodemakpowoe; Fante: Kakapenpen; Ga-Dangme: Apototso; Hausa: Wada, Nzema: Bakapembene; Wassa: AneenePA25/UGSOP/GH177RootsThe roots are boiled and the extract obtained are instilled into the nose
Rubus fruticosusRosaceaeBramblePA26/UGSOP/GH171Berries, leaves and flowersBlend dry leaves and mix with honey
Scoparia dulcis ScrophulariaceaePA27/UGSOP/GH171--
Sida acuta MalvaceaeBranchletsEwe: Afideme; Ga: Shwoboto; Twi: ObraneatutoPA28/UGSOP/GH171LeavesThe leaves are boiled and drank as required
Tapinanthus globiferrusLoranthaceaeParasitic TreeTwi: nkranpan Mole: WelebePA29/UGSOP/GH172Leaves; stemThe leaves/stem are boiled and the liquid obtained, drank as required
Terminalia catapaCombretaceaeabrɔfo nkateɛPA30/UGSOP/GH171Yellowed leavesThe leaves are boiled and the liquid drank as required
Tetrapleura tetrapteraFabaceaeTreeTwi: Prɛkesɛ, Zate: Zamturi; Anyi: Aprekese, Kyeke, Fante: Esem, Ewe: PrekesePA31/UGSOP/GH171SeedThe seeds are ground and the liquid extract drank as required
Vernonia amygdalinaAsteraceaeShrubGa:Tatso, Akpa, Dagbani: Biebingira, Ewe: Gbo, Gboti, Asante: Mbonasere, Mponasere; Nzema: Ayeanwole, Ga-Dangme: TatshoPA32/UGSOP/GH171LeavesA decoction is made from the either the fresh/dried leaves and drank as required


Botanical nameFamily CNS uses

Ageratum conyzoides Linn.,AsteraceaeAnalgesia [15, 42, 43]
Allium sativum Linn.LiliaceaeMotor coordination[44]; Analgesia [45]
Alstonia boonei De WildApocynaceaeAnalgesia [24]

Azadirachta indica A. JussMeliaceaeAnalgesia [25, 46]; Anxiolytic [47]; Alzheimer's disease [26]

Bertholletia excelsa H&BLecythidaceaeNone

Bidens pilosa Linn.AsteraceaeAnalgesia [48]
Blighia unijugata BakSapindaceaeNone

Cassia occidentalis Linn.CaesalpiniaceaeNone
Cinchona pubescens Vahl.RubiaceaeNone
Citrus aurantifolia SwingleRutaceaeNone

Cocos nucifera Linn.PalmaeAnalgesia [4951]

Corchorus olitorius Linn.TiliaceaeAnticonvulsant [52]

Cymbopogon citratus DC.GraminaeAnxiolytic [5356]; Sedative [53]; Anticonvulsant [53, 54, 57]; Analgesia [58]

Eucalyptus globulus Labill.MyrtaceaeNone
Khaya senegalensis (Desr.) A. Juss.MeliaceaeNone
Lantana camara Linn.VerbenaceaeAnxiolytic [59, 60]
Mangifera indica Linn. F.T.AAnacardiaceaeAnalgesia [61, 62];
Cognitive performance [63]
[64]; Neuroprotection, anticonvulsant [65]

Momordica charantia Linn.CucurbitaceaeAnalgesia [6668]; Antidepressant Anxiolytic [69]

Musa paradisiaca Walker et SillansMusaceaeNone

Nephrolepis cordifolia Linn PreslNephrolepidaceaeNone

Ocimum gratissimum Linn.LamiaceaeAnalgesia, antidepressant [7074]; and anxiolytic [75]

Passiflora edulis SimsPassifloraceaeAnxiolytic [7681] and sedative [78, 81, 82]

Persea Americana Mill F.W.T.ALauraceaeAnalgesia and anticonvulsant [83, 84]

Phyllanthus niruri Schum.et Thnn.EuphobiaceaeAnalgesia [85, 86]
Rauwolfia vomitoria Afz.ApocynaceaeAntipsychotic [16, 18, 29]
Rubus fruticosus Linn.RosaceaeNone
Scoparia dulcis Linn.ScrophulariaceaeAnalgesia [87, 88]
Sida acuta Burn F.MalvaceaeAnalgesia and antidepressant [89, 90]

Tapinanthus globiferus A. Rich.LoranthaceaeNone
Terminalia catappa Linn.CombretaceaeNone
Tetrapleura tetraptera Schum Taub.FabaceaeAnticonvulsant [91, 92], Analgesia [92]
Vernonia amygdalina Del. Cent. Pl. Afr.AsteraceaeAnalgesia [22]

3.5. Preparation and Administration of Herbal Products

The TAMs were prepared mostly as mixtures of two or more species. In some cases, however, the products were administered as monopreparations (prepared using a single plant species). The mode of preparation employed included decoction, infusion, and maceration, with decoction being the commonest (Table 4). While roots, fruits, flowers, stems, stem barks, whole plant of shrubs, etc. were all used in the preparation of these products (all together 42.4%), leaves (57.6%) were the commonest plant part used. The Ghanaian vernacular names of the plant species are listed in Table 5.

Given that most TMPs do not preserve these TAMs, they generally prepared the products only when required. The products were administered orally, nasally, or applied on the forehead for periods ranging from one week to several years or until the patient recovers. The TMPs mostly used patient feedback and disappearance of symptoms to assess treatment outcomes. Where there is only a partial recovery or treatment failure, the patients are often referred to the nearest hospital.

4. Discussion

Mental and neurological disorders remain a major public health concern [2]. The disease burden is even more prominent in the developing world, including Ghana [3, 5, 6]. Recent discoveries and clinical usage of the anticancer agent taxol and the antimalarial artemisinin derived from plants have boosted interest in natural products as templates for the development of novel drug scaffolds [19, 20]. TAMs are widely accepted in African communities and there appears to be an increasing reliance on these products [13]. In Ghana, TAMs are used as the main treatment paradigm for a variety of diseases, but they are also used as complements to other medicines or as dietary supplements [21]. However, thorough examination and documentation of the medicinal properties of these products against mental and neurological disorders is lacking.

In the present study, several plant species (32 species) used by local TMPs to treat mental and neurological disorders were reported, with most species belonging to the families Asteraceae, Apocynaceae, and Meliaceae. These are large and widespread plant families with several species. In particular, the Asteraceae family is of great importance due to its high numbers of medicinal species used in the treatment of a wide array of diseases including tuberculosis, malaria, and inflammatory disorders [11, 15, 22]. Members of the Asteraceae family are also known for their wide range of economically important products including cooking oils and phytochemicals such as sesquiterpene lactones, alkaloids, and tannins [23]. The family Apocynaceae also has a wide range of species that are of pharmacological importance, with some members synthesizing alkaloids useful against high blood pressure and inflammation and others synthesizing cardiac glycosides that affect heart function [24]. The family Meliaceae, on the other hand, is known for its species that are processed into important products including vegetable oil, as well as phytochemicals with anti-inflammatory, antioxidant, hepatoprotective, and cognitive-enhancing properties [25, 26].

While the plants used in treating CNS/PNS disorders in Ghana varied greatly, R. vomitoria Afz. was frequently mentioned (17.5%) by the TMPs who had knowledge of natural products for treating these disorders. Herbal preparations of this plant are also used by TMPs in other African countries for the treatment of mental disorders [27] and have been shown to be relatively safe with LD50 of 17.5 g/kg [28]. Remarkably, R. vomitoria Afz. has been found to have activity on the nervous system, especially on locomotor behavior, anxiety, and psychosis [16, 18, 29]. Reserpine, which is one of the numerous alkaloids of this species, has been used in the management of schizophrenia, hypertension, and psychiatric disorders [30]. Beyond its CNS effect, extracts from the plant are reported to have anticancer (due to the alstonine and β-carboline alkaloid) [31], antipyretic, anti-inflammatory [32], and antidiabetic activities [33].

The natural products used by the TMPs in treating mental and neurological disorders fall into the following broad categories: analgesics, anxiolytics, antidepressants, antipsychotics, and anticonvulsants. Of these, those with analgesic (pain relieving), anxiolytic (anti-anxiety), and anticonvulsant (anti-epileptic) effects were the most commonly used, and this possibly reflects the common disorders treated by the TMPs. In particular, half of the identified TAMs were analgesics, possibly suggesting that the TMPs were most often presented with patients suffering from headache, migraine, or other associated conditions. Headache or cephalalgia is used to describe pain in the head and could be a symptom of a number of different conditions associated with the head and neck [1]. Although limited studies have been conducted to assess the epidemiology of headache and migraine in Ghana and Africa, headache is quite common among Africans and is often exacerbated by the hot climate in most African countries [3436]. In assessing the profile of neurological disorders in an adult neurology clinic in Ghana, clinicians recorded a number of headache and migraine cases, although the frequency was found to be relatively low [37]. This low frequency was suggested to be due to the fact that primary headaches among Ghanaians are commonly reported to and managed by community pharmacists and primary healthcare physicians [37], although there are increasing reports indicating that several individuals with headache or migraine opt for traditional and herbal therapies [34, 35]. The analgesic species frequently used by the TMPs were A. conyzoides L. and O. gratissimum L. Also important are the anxiolytic (antianxiety) and anticonvulsant (antiepileptic) products that were often used by the TMPs, suggesting a potentially high prevalence of anxiety disorders and epilepsy and seizure disorders. Epilepsy, seizures, and anxiety disorders feature prominently among the mental and neurological conditions prevalent in Ghana [5, 37]. On the other hand, L. camara L. was the most frequently mentioned anxiolytic product, while C. citratus DC., M. indica L., T. tetraptera Schum Taub., and Persea Americana Mill were among the most frequently studied anticonvulsants used by the TMPs.

Given that drugs for managing mental disorders are often in shortage in Ghanaian psychiatric hospitals [6, 38], it may be important that TAMs whose therapeutic relevance has been confirmed experimentally are considered for clinical usage. The long history of TAMs usage in African societies with seemingly minimal adverse effects [21, 39] support this perspective. While clinical integration of TAMs may be beneficial, at present, this should be approached with caution due to the inadequacy of studies exploring their efficacy and safety. Therefore, increasing TAMs-based research in Ghana would be a crucial step towards rigorous establishment of their safety, therapeutic, and adverse reaction profiles.

The natural products identified in this study are a valuable collection of resources that may provide leads for drug discovery and development. However, a potential criticism of the traditional approach being employed by the TMPs in relation to the pharmaceutical industry approach to drug discovery is that whole plant extracts may contain several bioactive components, making it difficult to attribute therapeutic benefits and mechanism(s) of action to particular compounds (Rasoanaivo et al., 2011). Moreover, some plant extract components may be negative modulators of active drug ingredients, with adverse implications for drug potential. A feasible means to refine, extend, and enhance the beneficial effects of the plant products identified in this study is to isolate, screen, and characterize bioactive compounds responsible for the positive disease-modifying effects reported. On the other hand, it is possible that components of the different plant extracts used in combination may produce positive interactions leading to complementarity in observed therapeutic effects that are more effective than single components administered at equal doses. In such a case, plant extracts whose benefits are observed when used as combinations by the traditional healers should be explored further to identify their possible synergistic activities. For example, the antimalarial drugs Quinimax® (a combination of quinone, cinchonine, and quinidine) and Malarone® (proguanil and avoquone) are produced and marketed as synergistic complementary drugs (Bunnag et al., 1989; Fivelman et al., 2004). Further drug discovery and development research should be conducted on the reported plant products to identify lead compounds whose in vivo therapeutic capacities would be revealed in preclinical and clinical studies. This would enable the industrial-scale production and marketing of successful drug candidates following drug authority approval. The high cost of the drug discovery and development process would, however, require strengthening academia-industry collaborative research and better provision of research funding and infrastructure [5, 40, 41].

5. Conclusion

The identified natural products used in Ghanaian communities are a potential source of a novel class of drugs for the management of mental and neurological disorders. Many of the plant species used have been investigated for their CNS-specific pharmacologic effects, with the majority having analgesic, anxiolytic, or anticonvulsant properties. However, the most prominent and often used plant, R. vomitoria Afz., has potent antipsychotic properties. The increased reliance and the claimed therapeutic value of the identified TAMs indicate that there is an urgent need for the preservation and extensive investigation of these products to establish their clinical effectiveness. Such studies may help in the isolation and purification of the bioactive compounds, confirm the safety and tolerability of these products, and enable the clinical integration of TAMs.

Abbreviations

CNS:Central nervous system
GHAFTRAM:Ghana Federation of Traditional Medical Practitioners’ Association
GPs:General practitioners
TAMs:Traditional African medicines
TMPs:Traditional medicine practitioners.

Data Availability

The data used to support the findings of this study are available from the corresponding author upon request.

Conflicts of Interest

The authors declare that there are no conflicts of interest in the publication of this manuscript.

Acknowledgments

We are grateful to the leadership of GHAFRAM for facilitating the study and the herbal practitioners who spent time participating in the study. This study was funded by the Office of Research, Innovation and Development (ORID), University of Ghana, Accra, Ghana, grant awarded to Dr. Patrick Amoateng (reference number: URF/6/ILG-002/2012-2013). TKK is a member of the Midlands Integrative Biosciences Training Partnership, which is funded by the UK’s Biotechnology and Biological Sciences Research Council (BBSRC) Grant no. BB/J014532/1.

References

  1. M. I. Calvo and R. Y. Cavero, “Medicinal plants used for neurological and mental disorders in Navarra and their validation from official sources,” Journal of Ethnopharmacology, vol. 169, pp. 263–268, 2015. View at: Publisher Site | Google Scholar
  2. WHO, What Are Neurological Disorders, World Health Organization, 2016, http://www.who.int/features/qa/55/en/.
  3. A. Fekadu, C. Hanlon, E. Gebre-Eyesus et al., “Burden of mental disorders and unmet needs among street homeless people in Addis Ababa, Ethiopia,” BMC Medicine, vol. 12, no. 1, 2014. View at: Google Scholar
  4. D. Mamah, A. Owoso, A. W. Mbwayo et al., “Classes of psychotic experiences in kenyan children and adolescents,” Child Psychiatry & Human Development, vol. 44, no. 3, pp. 452–459, 2013. View at: Publisher Site | Google Scholar
  5. E. Quansah and T. K. Karikari, “Neuroscience-related research in ghana: A systematic evaluation of direction and capacity,” Metabolic Brain Disease, vol. 31, no. 1, pp. 11–24, 2016. View at: Publisher Site | Google Scholar
  6. M. Roberts, C. Mogan, and J. B. Asare, “An overview of Ghana’s mental health system: results from an assessment using the World Health Organization’s Assessment Instrument for Mental Health Systems (WHO-AIMS),” International Journal of Mental Health Systems, vol. 8, no. 1, p. 16, 2014. View at: Publisher Site | Google Scholar
  7. E. Quansah, E. Sarpong, and T. K. Karikari, “Disregard of neurological impairments associated with neglected tropical diseases in Africa,” eNeurologicalSci, vol. 3, pp. 11–14, 2016. View at: Publisher Site | Google Scholar
  8. F. Duah, P. Owusu, J. Knapp, D. Slatkin, and P. Schiff, “Constituents of West African Medicinal Plants,” Planta Medica, vol. 42, pp. 275–278, 1981. View at: Publisher Site | Google Scholar
  9. D. Dwuma-Badu, J. S. K. Ayim, T. T. Dabra et al., “Constituents of West African medicinal plants. XIV. Constituents of Piper guineense Schum. and Thonn,” Lloydia, vol. 39, no. 1, pp. 60–64, 1976. View at: Google Scholar
  10. K. D. Kwofie, N. H. Tung, M. Suzuki-Ohashi et al., “Antitrypanosomal activities and mechanisms of action of novel tetracyclic iridoids from Morinda lucida Benth,” Antimicrobial Agents and Chemotherapy, vol. 60, no. 6, pp. 3283–3290, 2016. View at: Publisher Site | Google Scholar
  11. J. M. Nguta, R. Appiah-Opong, A. K. Nyarko et al., “In vitro antimycobacterial and cytotoxic data on medicinal plants used to treat tuberculosis,” Data in Brief, vol. 7, pp. 1124–1130, 2016. View at: Publisher Site | Google Scholar
  12. M. A. Boateng, A. Danso-Appiah, B. K. Turkson, and B. P. Tersbøl, “Integrating biomedical and herbal medicine in Ghana - experiences from the Kumasi South Hospital: A qualitative study,” BMC Complementary and Alternative Medicine, vol. 16, no. 1, 2016. View at: Google Scholar
  13. WHO, WHO Global Atlas of Traditional, Complementary and Alternative Medicine, World Health Organization, 2005.
  14. Y. Adusi-Poku, L. K.-N. Okine, F. K. Hlortsi-Akakpo et al., “Assesssing herbal medical practitioners in professional qualifying examination in Ghana, a model,” African Journal of Traditional, Complementary and Alternative Medicines, vol. 7, no. 1, pp. 85–87, 2010. View at: Google Scholar
  15. A. A. Abena, G. S. Kintsangoula-Mbaya, J. Diantama, and D. Bioka, “Analgesic effects of Ageratum conyzoides extract in the rat,” L'Encéphale, vol. 19, no. 4, pp. 329–332, 1993. View at: Google Scholar
  16. S. A. Bisong, R. Brown, and E. E. Osim, “Comparative effects of Rauwolfia vomitoria and chlorpromazine on locomotor behaviour and anxiety in mice,” Journal of Ethnopharmacology, vol. 132, no. 1, pp. 334–339, 2010. View at: Publisher Site | Google Scholar
  17. J. R. S. Tabuti, C. B. Kukunda, and P. J. Waako, “Medicinal plants used by traditional medicine practitioners in the treatment of tuberculosis and related ailments in Uganda,” Journal of Ethnopharmacology, vol. 127, no. 1, pp. 130–136, 2010. View at: Publisher Site | Google Scholar
  18. S. Bisong, R. Brown, and E. Osim, “Comparative effects of Rauwolfia vomitoria and chlorpromazine on social behaviour and pain,” North American Journal of Medical Sciences, vol. 3, no. 1, pp. 48–54, 2011. View at: Publisher Site | Google Scholar
  19. C. Khanna, M. Rosenberg, and D. M. Vail, “A review of paclitaxel and novel formulations including those suitable for use in dogs,” Journal of Veterinary Internal Medicine, vol. 29, no. 4, pp. 1006–1012, 2015. View at: Publisher Site | Google Scholar
  20. L. H. Miller and X. Su, “Artemisinin: discovery from the Chinese herbal garden,” Cell, vol. 146, no. 6, pp. 855–858, 2011. View at: Publisher Site | Google Scholar
  21. J. M. Nguta, R. Appiah-Opong, A. K. Nyarko, D. Yeboah-Manu, and P. G. A. Addo, “Medicinal plants used to treat TB in Ghana,” International Journal of Mycobacteriology, vol. 4, no. 2, pp. 116–123, 2015. View at: Publisher Site | Google Scholar
  22. A. A. Adedapo, O. J. Aremu, and A. A. Oyagbemi, “Anti-Oxidant, anti-inflammatory and antinociceptive properties of the acetone leaf extract of Vernonia Amygdalina in some laboratory animals,” Advanced Pharmaceutical Bulletin, vol. 4, pp. 591–598, 2014. View at: Google Scholar
  23. S. Guenne, N. Ouattara, A. Hilou, J. F. Millogo, and O. G. Nacoulma, “Antioxidant, enzyme inhibition activities and polyphenol contents of three Asteraceae species used in Burkina Faso traditionally medicine,” International Journal of Pharmacy and Pharmaceutical Sciences, vol. 3, no. 5, pp. 524–528, 2011. View at: Google Scholar
  24. O. A. Olajide, S. O. Awe, J. M. Makinde et al., “Studies on the anti-inflammatory, antipyretic and analgesic properties of Alstonia boonei stem bark,” Journal of Ethnopharmacology, vol. 71, no. 1-2, pp. 179–186, 2000. View at: Publisher Site | Google Scholar
  25. K. Ilango, G. Maharajan, and S. Narasimhan, “Anti-nociceptive and anti-inflammatory activities of Azadirachta indica fruit skin extract and its isolated constituent azadiradione,” Natural Product Research, vol. 27, no. 16, pp. 1463–1467, 2013. View at: Publisher Site | Google Scholar
  26. R. Maiti, S. Kumar, S. Acharya, and M. Raghavendra, “Role of aqueous extract of Azadirachta indica leaves in an experimental model of Alzheimers disease in rats,” International Journal of Applied and Basic Medical Research, vol. 3, no. 1, p. 37, 2013. View at: Publisher Site | Google Scholar
  27. M. I. Akpanabiatu, I. B. Umoh, E. U. Eyong, E. E. Edet, and F. E. Uboh, “Influence of Rauwolfia vomitoria root bark on cardiac enzymes o normal Wistar albino rats,” Biopharmaceuticals, vol. 14, pp. 273–278, 2006. View at: Google Scholar
  28. A. O. Olatokunboh, Y. O. Kayode, and O. K. Adeola, “Anticonvulsant activity of Rauvolfia Vomitoria (Afzel),” African Journal of Pharmacy and Pharmacology, vol. 3, no. 6, pp. 319–322, 2009. View at: Google Scholar
  29. S. A. Bisong, R. E. Brown, and E. E. Osim, “Comparative extrapyramidal effects of Rauwolfia vomitoria, chlorpromazine and reserpine in mice,” Journal of Natural Medicines, vol. 67, no. 1, pp. 107–112, 2013. View at: Publisher Site | Google Scholar
  30. F. López-Muñoz, V. S. Bhatara, C. Álamo, and E. Cuenca, “Historical approach to reserpine discovery and its introduction in psychiatry,” Actas Españolas de Psiquiatría, vol. 32, no. 6, pp. 387–395, 2004. View at: Google Scholar
  31. D. L. Bemis, J. L. Capodice, P. Gorroochurn, A. E. Katz, and R. Buttyan, “Anti-prostate cancer activity of a β-carboline alkaloid enriched extract from Rauwolfia vomitoria,” International Journal of Oncology, vol. 29, no. 5, pp. 1065–1073, 2006. View at: Google Scholar
  32. G. Kweifio-Okai, D. Bird, B. Field et al., “Antiinflammatory activity of a Ghanaian antiarthritic herbal preparation: III,” Journal of Ethnopharmacology, vol. 46, no. 1, pp. 7–15, 1995. View at: Publisher Site | Google Scholar
  33. J. I. A. Campbell, A. Mortensen, and P. Mølgaard, “Tissue lipid lowering-effect of a traditional Nigerian anti-diabetic infusion of Rauwolfia vomitoria foilage and Citrus aurantium fruit,” Journal of Ethnopharmacology, vol. 104, no. 3, pp. 379–386, 2006. View at: Publisher Site | Google Scholar
  34. R. T. Haimanot, “Headache in the Tropics: Sub-Saharan Africa,” in Handbook of Headache, P. Martelletti and T. J. Steiner, Eds., pp. 533–540, Springer, Milan, 2011. View at: Google Scholar
  35. T. Haimanot, B. Seraw, L. Forsgren, J. Ekstedt, and K. Ekbom, “Migraine, chronic tension-type headache, and cluster headache in an ethiopian rural community,” Cephalalgia, vol. 15, no. 6, pp. 482–488, 1995. View at: Publisher Site | Google Scholar
  36. B. O. Osuntokun, B. S. Schoenberg, V. Nottidge et al., “Migraine headache in a rural community in nigeria: Results of a pilot study,” Neuroepidemiology, vol. 1, no. 1, pp. 31–39, 1982. View at: Publisher Site | Google Scholar
  37. F. S. Sarfo, J. Akassi, E. Badu, A. Okorozo, B. Ovbiagele, and A. Akpalu, “Profile of neurological disorders in an adult neurology clinic in Kumasi, Ghana,” eNeurologicalSci, vol. 3, pp. 69–74, 2016. View at: Publisher Site | Google Scholar
  38. D. Silberberg and E. Katabira, “Neurological Disorders,” in Disease and Mortality in Sub-Saharan Africa, D. T. Jamison, R. G. Feachem, M. W. Makgoba, E. R. Bos, F. K. Baingana, K. J. Hofman et al., Eds., World Bank, Washington, DC, USA, 2nd edition, 2006, http://www.ncbi.nlm.nih.gov/books/NBK2295/. View at: Google Scholar
  39. L. J. McGaw, N. Lall, J. J. M. Meyer, and J. N. Eloff, “The potential of South African plants against Mycobacterium infections,” Journal of Ethnopharmacology, vol. 119, no. 3, pp. 482–500, 2008. View at: Publisher Site | Google Scholar
  40. T. K. Karikari, A. E. Cobham, and I. S. Ndams, “Building sustainable neuroscience capacity in Africa: the role of non-profit organisations,” Metabolic Brain Disease, 2015. View at: Publisher Site | Google Scholar
  41. E. Quansah and T. K. Karikari, “Motor neuron diseases in sub-saharan africa: the need for more population-based studies,” BioMed Research International, vol. 2015, Article ID 298409, 9 pages, 2015. View at: Google Scholar
  42. H. Hossain, U. K. Karmakar, S. K. Biswas et al., “Antinociceptive and antioxidant potential of the crude ethanol extract of the leaves of Ageratum conyzoides grown in Bangladesh,” Pharmaceutical Biology, vol. 51, no. 7, pp. 893–898, 2013. View at: Publisher Site | Google Scholar
  43. L. A. Yamamoto, J. C. Soldera, J. A. Emim, R. O. Godinho, C. Souccar, and A. J. Lapa, “Pharmacological screening of Ageratum conyzoides L. (mentrasto),” Memórias do Instituto Oswaldo Cruz, vol. 86, no. 2, pp. 145–147, 1991. View at: Publisher Site | Google Scholar
  44. M. Aminuddin, G. Partadiredja, and D. C. R. Sari, “The effects of black garlic (Allium sativum L.) ethanol extract on the estimated total number of Purkinje cells and motor coordination of male adolescent Wistar rats treated with monosodium glutamate,” Anatomical Science International, vol. 90, no. 2, pp. 75–81, 2014. View at: Publisher Site | Google Scholar
  45. G. R. Kumar and K. P. Reddy, “Reduced nociceptive responses in mice with alloxan induced hyperglycemia after garlic (Allium sativum Linn.) treatment,” Indian Journal of Experimental Biology (IJEB), vol. 37, no. 7, pp. 662–666, 1999. View at: Google Scholar
  46. N. Khanna, M. Goswami, P. Sen, and A. Ray, “Antinociceptive action of Azadirachta indica (Neem) in mice: Possible mechanisms involved,” Indian Journal of Experimental Biology (IJEB), vol. 33, no. 11, pp. 848–850, 1995. View at: Google Scholar
  47. A. K. Jaiswal, S. K. Bhattacharya, and S. B. Acharya, “Anxiolytic activity of Azadirachta indica leaf extract in rats,” Indian Journal of Experimental Biology, vol. 32, no. 7, pp. 489–491, 1994. View at: Google Scholar
  48. A. F. Fotso, F. Longo, P. D. D. Djomeni et al., “Analgesic and antiinflammatory activities of the ethyl acetate fraction of Bidens pilosa (Asteraceae),” Inflammopharmacology, vol. 22, no. 2, pp. 105–114, 2014. View at: Publisher Site | Google Scholar
  49. D. S. Alviano, K. F. Rodrigues, S. G. Leitão et al., “Antinociceptive and free radical scavenging activities of Cocos nucifera L. (Palmae) husk fiber aqueous extract,” Journal of Ethnopharmacology, vol. 92, no. 2-3, pp. 269–273, 2004. View at: Publisher Site | Google Scholar
  50. S. Naskar, U. K. Mazumder, G. Pramanik, P. Saha, P. K. Haldar, and M. Gupta, “Evaluation of antinociceptive and anti-inflammatory activity of hydromethanol extract of cocos nucifera l.,” Inflammopharmacology, vol. 21, no. 1, pp. 31–35, 2013. View at: Publisher Site | Google Scholar
  51. S. Rinaldi, D. O. Silva, F. Bello et al., “Characterization of the antinociceptive and anti-inflammatory activities from Cocos nucifera L. (Palmae),” Journal of Ethnopharmacology, vol. 122, no. 3, pp. 541–546, 2009. View at: Publisher Site | Google Scholar
  52. M. Gupta, U. K. Mazumder, D. Pal, S. Bhattacharya, and S. Chakrabarty, “Studies on brain biogenic amines in methanolic extract of Cuscuta reflexa Roxb. and Corchorus olitorius linn. sees treated mice,” Acta Poloniae Pharmaceutica. Drug Research, vol. 60, no. 3, pp. 207–210, 2003. View at: Google Scholar
  53. M. M. Blanco, C. A. R. A. Costa, A. O. Freire, J. G. Santos Jr., and M. Costa, “Neurobehavioral effect of essential oil of Cymbopogon citratus in mice,” Phytomedicine, vol. 16, no. 2-3, pp. 265–270, 2009. View at: Publisher Site | Google Scholar
  54. E. A. Carlini, J. De D.P. Contar, A. R. Silva-Filho, N. G. Da Silveira-Filho, M. L. Frochtengarten, and O. F. A. Bueno, “Pharmacology of lemongrass (Cymbopogon citratus Stapf). I. Effects of teas prepared from the leaves on laboratory animals,” Journal of Ethnopharmacology, vol. 17, no. 1, pp. 37–64, 1986. View at: Publisher Site | Google Scholar
  55. C. A. R. D. A. Costa, D. O. Kohn, V. M. De Lima, A. C. Gargano, J. C. Flório, and M. Costa, “The GABAergic system contributes to the anxiolytic-like effect of essential oil from Cymbopogon citratus (lemongrass),” Journal of Ethnopharmacology, vol. 137, no. 1, pp. 828–836, 2011. View at: Publisher Site | Google Scholar
  56. J. Leite, M. De Lourdes V. Seabra, E. Maluf et al., “Pharmacology of lemongrass (Cymbopogon citratus Stapf). III. Assessment of eventual toxic, hypnotic and anxiolytic effects on humans,” Journal of Ethnopharmacology, vol. 17, no. 1, pp. 75–83, 1986. View at: Publisher Site | Google Scholar
  57. M. R. Silva, R. M. Ximenes, J. G. M. da Costa, L. K. A. M. Leal, A. A. de Lopes, and G. S. de Barros Viana, “Comparative anticonvulsant activities of the essential oils (EOs) from Cymbopogon winterianus Jowitt and Cymbopogon citratus (DC) Stapf. in mice,” Naunyn-Schmiedeberg's Archives of Pharmacology, vol. 381, no. 5, pp. 415–426, 2010. View at: Publisher Site | Google Scholar
  58. G. S. B. Viana, T. G. Vale, R. S. N. Pinho, and F. J. A. Matos, “Antinociceptive effect of the essential oil from Cymbopogon citratus in mice,” Journal of Ethnopharmacology, vol. 70, no. 3, pp. 323–327, 2000. View at: Publisher Site | Google Scholar
  59. I. Kazmi, M. Afzal, B. Ali, Z. A. Damanhouri, A. Ahmaol, and F. Anwar, “Anxiolytic potential of ursolic acid derivative-a stearoyl glucoside isolated from Lantana camara L. (verbanaceae),” Asian Pacific Journal of Tropical Medicine, vol. 6, no. 6, pp. 433–437, 2013. View at: Publisher Site | Google Scholar
  60. I. Kazmi, G. Gupta, M. Afzal, M. Rahman, and F. Anwar, “Pharmacological evaluation of anxiolytic activity of ursolic acid stearoyl glucoside isolated from lantana camara,” CNS Neuroscience & Therapeutics, vol. 18, no. 8, pp. 707-708, 2012. View at: Publisher Site | Google Scholar
  61. G. Garrido, D. Gonzalez, C. Delporte et al., “Analgesic and anti-inflammatory effects of Mangifera indica L. extract (Vimang),” Phytotherapy Research, vol. 15, no. 1, pp. 18–21, 2001. View at: Publisher Site | Google Scholar
  62. M. A. A. Khan and M. T. Islam, “Analgesic and cytotoxic activity of Acorus calamus L., Kigelia pinnata L., Mangifera indica L. and Tabernaemontana divaricata L.,” Journal of Pharmacy and Bioallied Sciences, vol. 4, no. 2, pp. 149–154, 2012. View at: Publisher Site | Google Scholar
  63. S. Kumar, K. K. Maheshwari, and V. Singh, “Effects of Mangifera indica fruit extract on cognitive deficits in mice,” Journal of Environmental Biology, vol. 30, pp. 563–566, 2009. View at: Google Scholar
  64. Y. Lemus-Molina, M. V. Sánchez-Gómez, R. Delgado-Hernández, and C. Matute, “Mangifera indica L. extract attenuates glutamate-induced neurotoxicity on rat cortical neurons,” NeuroToxicology, vol. 30, no. 6, pp. 1053–1058, 2009. View at: Publisher Site | Google Scholar
  65. G. L. Viswanatha, C. G. Mohan, H. Shylaja, H. C. Yuvaraj, and V. Sunil, “Anticonvulsant activity of 1,2,3,4,6-penta-O-galloyl-β-d-glucopyranose isolated from leaves of Mangifera indica,” Naunyn-Schmiedeberg's Archives of Pharmacology, vol. 386, no. 7, pp. 599–604, 2013. View at: Publisher Site | Google Scholar
  66. A. R. Biswas, S. Ramaswamy, and J. S. Bapna, “Analgesic effect of Momordica charantia seed extract in mice and rats,” Journal of Ethnopharmacology, vol. 31, no. 1, pp. 115–118, 1991. View at: Publisher Site | Google Scholar
  67. V. Jain, A. Pareek, N. Paliwal, Y. Ratan, A. S. Jaggi, and N. Singh, “Antinociceptive and antiallodynic effects of momordica charantia L. in tibial and sural nerve transection-induced neuropathic pain in rats,” Nutritional Neuroscience, vol. 17, no. 2, pp. 88–96, 2014. View at: Publisher Site | Google Scholar
  68. R. Patel, N. Mahobia, N. Upwar, N. Waseem, H. Talaviya, and Z. Patel, “Analgesic and antipyretic activities of Momordica charantia linn. fruits,” Journal of Advanced Pharmaceutical Technology & Research, vol. 1, no. 4, pp. 415–418, 2010. View at: Publisher Site | Google Scholar
  69. I. O. Ishola, A. A. Akinyede, and A. M. Sholarin, “Antidepressant and anxiolytic properties of the methanolic extract of Momordica charantia Linn (Cucurbitaceae) and its mechanism of action,” Drug Research, vol. 64, no. 7, pp. 368–376, 2014. View at: Publisher Site | Google Scholar
  70. P. I. Aziba, D. Bass, and Y. Elegbe, “Pharmacological investigation of Ocimum gratissimum in rodents,” Phytotherapy Research, vol. 13, no. 5, pp. 427–429, 1999. View at: Publisher Site | Google Scholar
  71. L. I. G. Paula-Freire, M. L. Andersen, G. R. Molska, D. O. Köhn, and E. L. A. Carlini, “Evaluation of the antinociceptive activity of ocimum gratissimum L. (Lamiaceae) essential oil and its isolated active principles in mice,” Phytotherapy Research, vol. 27, no. 8, pp. 1220–1224, 2013. View at: Publisher Site | Google Scholar
  72. M. Rabelo, E. P. Souza, P. M. G. Soares, A. V. Miranda, F. J. A. Matos, and D. N. Criddle, “Antinociceptive properties of the essential oil of Ocimum gratissimum L. (Labiatae) in mice,” Brazilian Journal of Medical and Biological Research, vol. 36, no. 4, pp. 521–524, 2003. View at: Publisher Site | Google Scholar
  73. Y. Tanko, G. M. Magaji, M. Yerima, R. A. Magaji, and A. Mohammed, “Anti-nociceptive and anti-inflammatory activities of aqueous leaves extract of Ocimum Gratissimum (Labiate) in Rodents,” African Journal of Traditional, Complementary and Alternative Medicines, vol. 5, no. 2, pp. 141–146, 2008. View at: Google Scholar
  74. M. Zamin, “An analgesic and hepatoprotective plant: Ocimum gratissimum,” Pakistan Journal of Biological Sciences, vol. 14, no. 20, pp. 954-955, 2011. View at: Publisher Site | Google Scholar
  75. C. O. Okoli, A. C. Ezike, O. C. Agwagah, and P. A. Akah, “Anticonvulsant and anxiolytic evaluation of leaf extracts of Ocimum gratissimum, a culinary herb,” Pharmacognosy Research, vol. 2, no. 1, pp. 36–40, 2010. View at: Publisher Site | Google Scholar
  76. P. R. Barbosa, S. S. Valvassori, C. L. Bordignon Jr. et al., “The aqueous extracts of Passiflora alata and Passiflora edulis reduce anxiety-related behaviors without affecting memory process in rats,” Journal of Medicinal Food, vol. 11, no. 2, pp. 282–288, 2008. View at: Publisher Site | Google Scholar
  77. M. Coleta, M. T. Batista, M. G. Campos et al., “Neuropharmacological evaluation of the putative anxiolytic effects of Passiflora edulis Sims, its sub-fractions and flavonoid constituents,” Phytotherapy Research, vol. 20, no. 12, pp. 1067–1073, 2006. View at: Publisher Site | Google Scholar
  78. J. Deng, Y. Zhou, M. Bai, H. Li, and L. Li, “Anxiolytic and sedative activities of Passiflora edulis f. flavicarpa,” Journal of Ethnopharmacology, vol. 128, no. 1, pp. 148–153, 2010. View at: Publisher Site | Google Scholar
  79. A. Otify, C. George, A. Elsayed, and M. A. Farag, “Mechanistic evidence of Passiflora edulis (Passifloraceae) anxiolytic activity in relation to its metabolite fingerprint as revealed via LC-MS and chemometrics,” Food & Function, vol. 6, no. 12, pp. 3807–3817, 2015. View at: Publisher Site | Google Scholar
  80. R. D. Petry, F. Reginatto, and F. de-Paris, “Comparative pharmacological study of hydroethanol extracts of Passiflora alata and Passiflora edulis leaves,” Phytotherapy Research, vol. 15, no. 2, pp. 162–164, 2001. View at: Publisher Site | Google Scholar
  81. L. M. Sena, S. M. Zucolotto, F. H. Reginatto, E. P. Schenkel, and T. C. M. De Lima, “Neuropharmacological activity of the pericarp of Passiflora edulis flavicarpa Degener: Putative involvement of C-glycosylflavonoids,” Experimental Biology and Medicine, vol. 234, no. 8, pp. 967–975, 2009. View at: Publisher Site | Google Scholar
  82. N. Klein, A. C. Gazola, T. C. M. De Lima, E. Schenkel, K. Nieber, and V. Butterweck, “Assessment of sedative effects of passiflora edulis f. flavicarpa and passiflora alata extracts in mice, measured by telemetry,” Phytotherapy Research, vol. 28, no. 5, pp. 706–713, 2014. View at: Publisher Site | Google Scholar
  83. O. O. Adeyemi, S. O. Okpo, and O. O. Ogunti, “Analgesic and anti-inflammatory effects of the aqueous extract of leaves of Persea americana Mill (Lauraceae),” Fitoterapia, vol. 73, no. 5, pp. 375–380, 2002. View at: Publisher Site | Google Scholar
  84. J. A. O. Ojewole and G. J. Amabeoku, “Anticonvulsant effect of Persea americana mill (Lauraceae) (avocado) leaf aqueous extract in mice,” Phytotherapy Research, vol. 20, no. 8, pp. 696–700, 2006. View at: Publisher Site | Google Scholar
  85. J. Moreira, L. C. Klein-Júnior, V. Cechinel Filho, and F. de Campos Buzzi, “Anti-hyperalgesic activity of corilagin, a tannin isolated from Phyllanthus niruri L. (Euphorbiaceae),” Journal of Ethnopharmacology, vol. 146, no. 1, pp. 318–323, 2013. View at: Publisher Site | Google Scholar
  86. I. C. Obidike, O. A. Salawu, M. Ndukuba, C. O. Okoli, and U. A. Osunkwo, “The anti-inflammatory and antinociceptive properties of the chloroform fraction from Phyllanthus niruri plant is mediated via the peripheral nervous system,” Journal of Dietary Supplements, vol. 7, no. 4, pp. 341–350, 2010. View at: Publisher Site | Google Scholar
  87. M. Ahmed, H. A. Shikha, S. K. Sadhu, M. T. Rahman, and B. K. Datta, “Analgesic, diuretic, and anti-inflammatory principle from Scoparia dulcis,” Die Pharmazie, vol. 56, pp. 657–660, 2001. View at: Google Scholar
  88. S. M. Freire, L. M. Torres, N. F. Roque, C. Souccar, and A. J. Lapa, “Analgesic activity of a triterpene isolated from Scoparia dulcis L. (vassourinha),” Memórias do Instituto Oswaldo Cruz, vol. 86, no. 2, pp. 149–151, 1991. View at: Publisher Site | Google Scholar
  89. G. F. Ibironke, A. S. Umukoro, and D. C. Ajonijebu, “Central nervous system activity of the ethanol leaf extract of Sida acuta in rats,” African Journal of Medicine and Medical Sciences, vol. 43, pp. 11–16, 2014. View at: Google Scholar
  90. K. Konaté, I. H. N. Bassolé, A. Hilou et al., “Toxicity assessment and analgesic activity investigation of aqueous acetone extracts of Sida acuta Burn f . and Sida cordifolia L. (Malvaceae), medicinal plants of Burkina Faso,” BMC Complementary and Alternative Medicine, vol. 12, Article ID 120, 2012. View at: Publisher Site | Google Scholar
  91. J. I. Nwaiwu and P. A. Akah, “Anticonvulsant activity of the volatile oil from the fruit of tetrapleura tetraptera,” Journal of Ethnopharmacology, vol. 18, no. 2, pp. 103–107, 1986. View at: Publisher Site | Google Scholar
  92. J. A. O. Ojewole, “Analgesic and anticonvulsant properties of Tetrapleura tetraptera (Taub) (Fabaceae) fruit aqueous extract in mice,” Phytotherapy Research, vol. 19, no. 12, pp. 1023–1029, 2005. View at: Publisher Site | Google Scholar

Copyright © 2018 Patrick Amoateng et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


More related articles

 PDF Download Citation Citation
 Download other formatsMore
 Order printed copiesOrder
Views11630
Downloads1400
Citations

Related articles

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.